Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Overall Survival Analysis Between African-American and Caucasian Men with mCRPC

August 17th 2018

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses an analysis of overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Dr. Choyke on Differences Between PET Scans in Prostate Cancer

August 14th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the differences between PET scans in prostate cancer.

Survival Disparity Analysis Yields Unexpected Findings in mCRPC

August 13th 2018

Susan Halabi, PhD, discusses the unexpected results of a survival disparity analysis of African-American and Caucasian patients with metastatic castration-resistant prostate cancer.

Dr. Hussain on Potential of Enzalutamide in Prostate Cancer

August 9th 2018

Maha H. Hussain, MD, FACP, Genevieve Teuton Professor of Medicine, deputy director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the potential of enzalutamide in prostate cancer.

Expert Emphasizes Inclusivity in Prostate Cancer Trials

August 8th 2018

Daniel J. George, MD, discusses the findings from Abi Race and the implications they have on clinical trials in prostate cancer moving forward.

Dr. Samuelson on the Comorbidities that Affect Treatment Decisions in Prostate Cancer

August 8th 2018

Scott Samuelson, MD, medical oncologist at Utah Cancer Specialists, discusses the comorbidities that may affect treatment decisions for patients with metastatic prostate cancer.

Rethinking the Prostate Cancer Paradigm in the Urology Community

August 4th 2018

Raoul S. Concepcion, MD, FACS, discusses how to sort through the massive amount of data in the urology space, gain a basic understanding of its significance, and determine its clinical utility.

Dr. Yu on the Future of Castration-Sensitive Prostate Cancer

August 2nd 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the future of castration-sensitive prostate cancer.

ASCO Adds New Combos for Metastatic Noncastrate Prostate Cancer

July 31st 2018

Use of androgen deprivation therapy in combination with docetaxel or abiraterone in newly diagnosed cases of metastatic noncastrate prostate cancer is recommended in recently updated ASCO guidelines.

Practice in South Texas Offers Vertically Integrated Cancer Care

July 30th 2018

Providing comprehensive, compassionate, cost-effective care has been the guiding principle of Urology San Antonio. The practice manages over 200,000 visits and establishes relationships with more than 22,000 new patients each year.

Regulatory Decisions Propel Nonmetastatic CRPC Paradigm Forward

July 26th 2018

Mehmood Hashmi, MD, discusses the newly defined landscape of nonmetastatic castration-resistant prostate cancer, the potential with immunotherapy, and emerging imaging modalities.

Dr. Hussain on the Treatment of Nonmetastatic CRPC

July 25th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Vogelzang Discusses PROSPECT Trial for Prostate Cancer

July 20th 2018

Nicholas J. Vogelzang, MD, site research leader for Comprehensive Cancer Centers of Nevada, member of US Oncology Network, 2018 Giant of Cancer Care

Dr. Hashmi on Immunotherapy in Prostate Cancer

July 18th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer.

CTC AR-V7 Assay Shows Promise as Treatment Guide in mCRPC

July 17th 2018

An assay for nuclear-localized androgen receptor splice variant 7 protein in circulating tumor cells identified patients with metastatic castration-resistant prostate cancer who had better outcomes from treatment with taxanes, and those who did better with androgen receptor-signaling inhibitors.

FDA Approves Enzalutamide for Nonmetastatic CRPC

July 14th 2018

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

July 13th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

Dr. Hashmi on Imaging Modalities in Prostate Cancer

July 13th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses imaging modalities in prostate cancer.

Yu Shares Insight on Recent Advances in Castration-Sensitive Prostate Cancer

July 10th 2018

Evan Ya-Wen Yu, MD, discusses the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between treatment with abiraterone and docetaxel for this population.

Dr. Hashmi on Prostate Cancer Abstracts From the 2018 ASCO Annual Meeting

July 10th 2018

Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the exciting abstracts in prostate cancer that were presented at the 2018 ASCO Annual Meeting.